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Abstract: In this guideline, the International Right Heart Foundation Working Group moves a step forward
to develop a common language to describe the development and defects that exemplify the common syn-
drome of right heart failure. We ﬁrst propose fundamental deﬁnitions of the distinctive components of the
right heart circulation and provide consensus on a universal deﬁnition of right heart failure. These deﬁnitions
will form the foundation for describing a uniform nomenclature for right heart circulatory failure with a view
to foster collaborative research initiatives and conjoint education in an effort to provide insight into mecha-
nisms of disease unique to the right heart.
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The right ventricle may be said to be made for the sake of transmitting blood through the lungs, not for nourishing them.
—William Harvey, Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus, 1628
Even as progress in understanding left heart failure has
ensued unfettered, the right heart has, for many years,
been relegated to a bystander chamber. This downgrade
has been accepted for decades under the presumption
that the right heart is a conduit structure that is a sec-
ondary actor in the interplay of heart failure, with pri-
macy accorded to the left ventricle. Yet the sentinel role of
right heart failure in determining functional, end-organ,
and clinical outcomes has become the subject of increas-
ing recent inquiry.
1 We now recognize that the right heart
is structurally discrete in its anatomic, electrical, and cel-
lular conﬁguration; develops failure often due to distinct
pathobiologic pathways that are separate from the left ven-
tricle; and plays a central role in determining prognosis
even as therapeutic success in addressing left ventricular
dysfunction is demonstrated.
2 Uniquely, therapy that in-
ﬂuences the left ventricle favorably may not impact the
dysfunctional right ventricle, and vice versa.
3
The right ventricle and left ventricle are anatomically,
physiologically, and functionally distinct. The right ven-
tricle is anatomically composed of 3 distinct portions:
4
the ﬁrst portion is the inlet, which includes the tricuspid
valve, the chordae tendinae, and papillary muscles; the
second portion is the trabeculated apical myocardium;
and ﬁnally, the infundibulum, or conus, constitutes the
outlet region. The shape of the right ventricle is complex:
it appears triangular from the side and is crescent shaped
in cross section. There are 2 layers of the right ventricular
myocardium. The ﬁbers of the superﬁcial layer of the
right ventricle are arranged circumferentially in a direc-
tion that is parallel to the atrioventricular (AV) groove in
continuity with the left ventricle. The deep muscle ﬁbers
of the right ventricle are longitudinally aligned base to
apex (in contrast to the left ventricle, where oblique ﬁ-
bers are found superﬁcially, longitudinal ﬁbers on the endo-
cardium, and circumferential ﬁbers in between). Haddad
and colleagues
4 elegantly described the morphologic dif-
ferences between the left and right ventricles as follows:
(1) a more apically situated hinge point of the septal leaf-
let of the tricuspid valve relative to the anterior leaﬂet of
the mitral valve, (2) the presence of a moderator band in
the right ventricle cavity, (3) more than 2 papillary mus-
cles, (4) a trileaﬂet atrioventricular valve with septal attach-
ments, (5) predominantly coarse trabeculations, and (6) a
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valve from the pulmonic valve (as opposed to the aorto-
mitral continuity seen on the left). These anatomic struc-
tural differences indicate that the designs are intended
for distinct purposes on an evolutionary scale. Impor-
tantly, they provide insight into the biologic diversity that
explains the varied phenotypic reactions to hemodynamic
stressors.
Physiologically, the right ventricle is more uniquely
sensitive to afterload, demonstrates a trapezoid pressure-
volume curve (as opposed to a rectangular pressure-volume
loop for the left ventricle), and develops dysfunction by
many distinct pathways.
5 In the setting of an acute in-
crease in pulmonary arterial impedance, as encountered
in pulmonary embolism, the right ventricle demonstrates
evidence of a severe reduction in stroke volume with a nar-
row window of pressure increase.
6 When a left ventricular
assist device is placed and ventricular suction applied such
that the septum is moved into the left ventricular cavity,
one frequently has signiﬁcant right ventricular dysfunc-
tion even with reduced afterload.
7 Extrinsic compression,
as with pericardial constriction or effusion, can impede
right ventricular function by compressive dynamics and
lead to manifestations of heart failure.
8 In clinical syn-
dromes of congenital heart disease, one can exhibit the
syndrome of right-sided failure due to changes in ﬂow and
anatomic defects located within the right ventricle or in
anatomic areas preceding blood entry into this chamber.
5
In chronically raised afterload and pulmonary impedance,
the right ventricle demonstrates rather diverse responses,
with variable expression of dysfunction over time. Despite
these complex attributes, it is clear that development of
right-sided dysfunction portends a steep decline in prog-
nosis accompanied by multisystem organ failure, reflected
variably in clinical expression as the cardiorenal syndrome,
protein-losing enteropathy, and cardiac cachexia.
9-11
It has become obvious that the complex nature of right-
sided heart failure, the diverse pathways and multispecialty
involvement among distinct clinicians, such as cardiolo-
gists, pulmonologists, congenital heart disease experts, and
cardiothoracic surgeons, has enforced the development
of varying deﬁnitions that are uniformly resident within
silos and consequently cover a limited scope and clinical
need. To address this impediment to research and inno-
vation in right heart failure, leading experts from around the
world in the ﬁelds of congenital heart disease, pulmo-
nary vascular disease, congestive heart failure, and car-
diothoracic surgery came together under the aegis of the
newly founded International Right Heart Foundation with
the core mission of bringing this distinguished interdis-
ciplinary group of expert physician scientists together to
develop an integrative language that effectively captures
and describes right heart disease. The development of a
common language relevant to scientists and clinicians alike
was designed to foster collaborative research initiatives
and conjoint education in an effort to provide insight into
mechanisms of disease unique to the right heart while ad-
vancing patient care.
This group reached united consensus on the basic def-
initions concerning the right heart and further emphasized
that confusion between the commonly used nomenclature
of “right ventricular failure” and “right heart failure” must
be clariﬁed as follows and not used interchangeably.
Deﬁnition 1: distinction between right heart failure and
right ventricular failure. Right heart failure represents a dis-
turbance or dysfunction in any of the components that
constitute the right heart circulatory system (deﬁned be-
low). Thus, right ventricular failure, in contradistinction,
is one component (albeit major) of a pathophysiological en-
titythatcanresult in right heart circulatory failure.
Deﬁnition 2: components of the right heart system. The
“right heart circulatory system” is comprised of the sys-
temic veins up to the pulmonary capillaries—at which point
deoxygenated blood transitions to oxygenated blood. The
right heart system can be classiﬁed into systemic and pul-
monary circuits. The systemic circuit includes the systemic
veins, right atrium, coronary sinus (and cardiac venous
drainage), tricuspid valve, right ventricular free wall, right
ventricular outﬂow tract, and pulmonic valve. The pulmo-
nary circuit includes the main pulmonary artery post-
pulmonic valve and the secondary and tertiary branches
of the pulmonary arteries.
The “left heart circulatory system” is comprised of the
postpulmonary capillaries to the systemic arteries—at which
point oxygenated blood begins to shift to deoxygenated
blood. The left heart circulatory system is comprised of
the pulmonary veins, left atrium, mitral valve, left ven-
tricle, aortic valve, aorta, and systemic arteries (including
the coronary arteries). The pulmonary and systemic cap-
illary beds are shared between the two compartments on
the right- and left-sided circulatory system.
Deﬁnition 3: what is right heart failure? Wedeﬁne“right
heart failure” as a clinical syndrome due to an alteration of
structure and/or function of the right heart circulatory sys-
tem that leads to suboptimal delivery of blood ﬂow (high or
low) to the pulmonary circulation and/or elevated venous
pressures—at rest or withexercise.
Distinctively, this definition is broad and classiﬁes right
heart failure as a syndrome, which may result from ana-
tomic or physiologic aberrations, or both, from a variety
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Importantly, this deﬁnition allows for abnormalities to
manifest themselves clinically during exercise alone while
remaining quiescent during resting conditions. Further-
more, we believe that it is important to allow for a broad
deﬁnition that encompasses most disorders (ranging from
those that always involve the right ventricle to those that
may spare the right ventricle yet result in the manifest
clinical syndrome such as a pretricuspid lesion). However,
we do recognize that clinical exceptions to the rule always
exist (e.g., occlusive disease of the inferior vena cava). Thus,
it is our contention that this deﬁnition, as proposed, may
meet the goal of widest incorporation of pathologic sub-
strates and their clinical manifestation that inﬂuence clin-
ical expression in the right heart circulatory system.
Toward a comprehensive clinical nomenclature. The next
step to build upon these fundamental deﬁnitions is to
develop a comprehensive nomenclature that can be used
by clinicians to accurately standardize and discuss the etio-
anatomicophysiologic basis that results in clinical manifes-
tations of right heart failure. Current classiﬁcation systems
used to describe disease of the left heart are inadequate
Table 1. Development of a comprehensive nomenclature of right heart failure: framework, components, and issues
Components, issues
1. Etiology: What is the primary cause?
a. Draw upon existing classiﬁcation systems for congenital heart disease
b. Advance current descriptions of acquired etiologies (The novel aspect lies in the expanded deﬁnition of right heart failure to
include precardiac and postpulmonary valvular compartments.)
2. Anatomy: Where is the primary defect?
a. Describe the anatomic constituents of the right heart circulatory system
b. Describe the anatomic defects within the right heart circulatory system (systemic circuit and pulmonary circuit)
and left heart circulatory system
3. Physiology: What is the primary aberration?
a. Deﬁne the appropriate hemodynamic and nonhemodynamic deﬁnitions and assessments of 3 distinct
physiologic disturbances in the domains of preload stress, contractile insufﬁciency, and afterload stress
4. Clinical function: What is the clinical expression in the patient?
a. Functional class components
A. Subjective component
a. Patient’s reported symptom (modiﬁed NYHA functional class)
b. Assessment of patient’s activity proﬁle (sedentary, active, etc.)
c. Quality of life (most appropriate assessment to be determined)
B. Objective component
a. 6MWT (include Borg score, percent predicted value)
b. Pending results and/or clinical situation, proceed with cardiopulmonary stress test (CPEX) (availability,
safety, and consistency in interpretation of data presenting as barriers to be further discussed)
i. Assess hemodynamic and/or ventilator response/insufﬁciency
C. Modiﬁers to functional assessment (noncardiovascular contributors to symptoms)
a. Body mass index (BMI)
b. Orthopedic limitations
c. Systemic processes
b. How should secondary modiﬁers (secondary organ function) be incorporated?
i. Renal dysfunction, as measured by GFR?
ii. Hepatic dysfunction, as measured by MELD
(Should these elements be treated under physiologic aberrations or functional aspects?)
Note: NYHA: New York Heart Association; 6MWT: 6-minute walk test; CPEX: cardiopulmonary exercise test; GFR: glomerular
ﬁltration rate; MELD: model for end-stage liver disease.
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more, epidemiologic studies do not provide guidance by
which a classiﬁcation system distinct to the right heart
may be derived. However, past experiences can inform us
on developing a cogent structure of a framework to de-
velop this process. One such early attempt to categorize
heart disease was developed as a book in 1928 by Paul
Dudley White and Merrill M. Myers, whose work was ul-
timately published as a book in 1928 by the New York
Heart Association (NYHA), which classiﬁed cardiovas-
cular disease. The most recent version was published
in 1994.
12 Despite its ambiguities and vulnerability to
subjective assessment, it remains a hallowed system by
which to evaluate clinical cardiovascular disease and is of-
ten the endpoint of studies of investigational therapies.
13
The 5 essential elements of the NYHA classiﬁcation of
cardiovascular disease are etiology, anatomy, physiology,
functionalstatus,andobjective assessment. Using the same
elements and framework developed nearly a century ago,
we have put forward a structure for developing the clas-
siﬁcation system for right heart failure. The salient fea-
tures of this working structure (and questions that need
to be addressed), which will be reﬁned and developed in
2014 by the International Right HeartFoundation Nomen-
clature Working Group in partnership with sister organi-
zations and societies, are described in Table 1.
In summary, we believe that the International Right
Heart Foundation Working Group is poised to develop a
common language to describe the development and de-
fects that exemplify this important clinical syndrome. The
common fundamental deﬁnitions of components of the
right heart, distinction between the right heart and sub-
components (e.g., the right ventricle), and consensus on
a universal deﬁnition of right heart failure represent the
ﬁrst important steps toward scientiﬁc progress in this
area. We resonate with the declaration of Dr. Eugene
Braunwald at our ﬁrst consensus summit, where he poi-
gnantly professed the right heart as a “stepchild no more!”
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